Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
40.29
+0.39 (0.98%)
Jan 17, 2025, 4:00 PM EST - Market closed
Revolution Medicines Revenue
Revolution Medicines had revenue of $742.00K in the twelve months ending September 30, 2024, down -97.16% year-over-year. In the year 2023, Revolution Medicines had annual revenue of $11.58M, down -67.27%.
Revenue (ttm)
$742.00K
Revenue Growth
-97.16%
P/S Ratio
n/a
Revenue / Employee
$1,963
Employees
378
Market Cap
7.45B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
RVMD News
- 14 days ago - Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 6 weeks ago - Revolution Medicines: Risky Buy On Recent Share Price Dip - Seeking Alpha
- 6 weeks ago - Top 3 Health Care Stocks That Could Blast Off In December - Benzinga
- 6 weeks ago - Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 7 weeks ago - Revolution Medicines Announces Commencement of Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio - GlobeNewsWire
- 7 weeks ago - Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 - GlobeNewsWire